An Increase of Plasma Advanced Oxidation Protein Products Levels Is Associated with Cardiovascular Risk in Incident Peritoneal Dialysis Patients: A Pilot Study

• Published in: Oxidative medicine and cellular longevity 2015-01, Vol.2015 (2015), p.1-6
• Main Authors: Díez, Juan J., Selgas, Rafael, Iglesias, Pedro, del Peso, Gloria, Sánchez-Villanueva, Rafael, Grande, Cristina, Lindholm, Bengt, Carrero, Juan J., Bajo, Maria-Auxiliadora, Gonzalez, Elena, Díaz-Almirón, Mariana
• Format: Article
• Language: English
• Subjects: Adult; Advanced Oxidation Protein Products - analysis; Aged; Atherosclerosis; Biomarkers - blood; Cardiovascular diseases; Cardiovascular Diseases - blood; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - etiology; Diabetes; Female; Glomerular Filtration Rate; Grants; Heart attacks; Humans; Hypertension; Inflammation; Kidney diseases; Male; Medical prognosis; Medical research; Medicin och hälsovetenskap; Medicine, Experimental; Middle Aged; Molecular weight; Mortality; Oxidation; Oxidation-reduction reaction; Oxidative Stress; Pathogenesis; Patients; Peritoneal Dialysis; Pilot Projects; Plasma; Prevalence; Proteins; Risk Factors; Studies; Tumor necrosis factor-TNF
• ISSN: 1942-0900; 1942-0994; 1942-0994
• DOI: 10.1155/2015/219569

Advanced oxidation protein products (AOPPs) are considered as markers and even mediators of the proinflammatory effect of oxidative stress in uremia. We hypothesized that an increase of oxidative stress associated with peritoneal dialysis (PD), estimated by the variation of plasma AOPPs over time, might be associated with cardiovascular (CV) risk and overall prognosis. In 48 PD patients, blood samples were collected on two occasions: the first one in the first six months after starting PD therapy and the second one, one year after. The plasma AOPPs level variation over the first year on PD was significantly associated with CV antecedents and also with CV prognosis. In those patients in whom the AOPPs levels increased more than 50% above the baseline value, a significant association with past and future CV disease was confirmed. These patients had 4.7 times greater risk of suffering later CV disease than those with a smaller increase, even after adjusting for previous CV history. Our data suggest that the increase of AOPPs plasma level over the first year on PD is conditioned by CV antecedents but also independently predicts CV prognosis. AOPPs plasma levels seem to represent the CV status of PD patients with sufficient sensitivity to identify those with a clearly sustained higher CV risk.